Dennis Ausiello Net Worth

The estimated Net Worth of Dennis A Ausiello is at least $7.47 Milhão dollars as of 6 August 2024. Dennis Ausiello owns over 20,250 units of Alnylam Pharmaceuticals Inc stock worth over $5,339,297 and over the last 11 years he sold ALNY stock worth over $1,661,613. In addition, he makes $470,707 as Independent Director at Alnylam Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dennis Ausiello ALNY stock SEC Form 4 insiders trading

Dennis has made over 11 trades of the Alnylam Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 20,250 units of ALNY stock worth $2,423,520 on 6 August 2024.

The largest trade he's ever made was exercising 22,500 units of Alnylam Pharmaceuticals Inc stock on 21 November 2022 worth over $1,599,750. On average, Dennis trades about 2,765 units every 83 days since 2013. As of 6 August 2024 he still owns at least 20,386 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Dennis Ausiello stock trades at the bottom of the page.

Dennis Ausiello biography

Dr. Dennis A. Ausiello, M.D. is Independent Director of the Alnylam Pharmaceuticals, Inc. Dr. Ausiello has served as a member of our board of directors since April 2012. Dr. Ausiello serves as the Director of the Center for Assessment Technology and Continuous Health (CATCH), Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Massachusetts General Hospital, and served as the Chief of Medicine at Massachusetts General Hospital from 1996 to April 2013. Dr. Ausiello was the President of the Association of American Physicians in 2006. He is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences. He also serves as a director of Pfizer Inc. and Seres Therapeutics, Inc.

What is the salary of Dennis Ausiello?

As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Dennis Ausiello at Alnylam Pharmaceuticals Inc is $470,707. There are 17 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.

How old is Dennis Ausiello?

Dennis Ausiello is 74, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2012. There are 1 older and 19 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.

What's Dennis Ausiello's mailing address?

Dennis's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, eKevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Complete history of Dennis Ausiello stock trades at Alnylam Pharmaceuticals Inc, Seres Therapeutics Inc, ePfizer

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director